Clinical Trials Directory

Response-Adapted Therapy for Aggressive Non-Hodgkin's Lymphomas Based on Early [18F] FDG-PET Scanning

RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or carry cancer-killing substances to them. Drugs used in chemotherapy work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving rituximab together with combination chemotherapy may kill more cancer cells. PURPOSE: This phase II trial is studying how well giving rituximab together with combination chemotherapy works in treating patients with stage II, stage III, or stage IV diffuse large B-cell non-Hodgkin's lymphoma.

Stanford is not currently accepting new patients for this trial. You may want to check to see if other locations are recruiting.



  • biological : rituximab
  • biological : filgrastim
  • drug : vincristine
  • drug : etoposide
  • drug : ifosfamide
  • drug : prednisone
  • drug : cyclophosphamide
  • drug : carboplatin
  • drug : doxorubicin hydrochloride

Phase: Phase 2


Ages Eligible For Study:

18 Years - 70 Years

External Links

Explore related trials

Contact information

Primary Contact:

Lauren Pernicka 6507216977

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: